HYPOCHONDROPLASIA
Clinical trials for HYPOCHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new HYPOCHONDROPLASIA trials appear
Sign up with your email to follow new studies for HYPOCHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for boosting growth in kids with rare bone disorder
Disease control OngoingThis study tests a drug called vosoritide in 80 children aged 3 to 17 with hypochondroplasia, a condition that causes short stature. The goal is to see if it safely increases growth rate over one year compared to a placebo. Participants receive daily injections and are monitored …
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated May 17, 2026 12:27 UTC
-
New drug aims to boost growth in kids with rare bone disorder
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called infigratinib in 24 children with hypochondroplasia, a condition that causes short stature. The goal is to see if it can safely improve growth rate. The study has two phases: first, all children get the drug, then some get a placebo to compare result…
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with hypochondroplasia: Long-Term drug trial underway
Disease control ENROLLING_BY_INVITATIONThis study is for children with hypochondroplasia, a condition that causes short stature. It tests a drug called infigratinib over the long term to see if it is safe and helps with growth. Participants must have already completed a related earlier study. The goal is to understand…
Matched conditions: HYPOCHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 13, 2026 16:00 UTC